Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 853
New Product Introduction Update
A graphic showing ongoing studies of injectable cabotegravir and the dapivirine vaginal ring in eastern and southern Africa.
Top Vaccines Funders
Total US dollars invested by each of the top 10 global funders of vaccine research in 2022.
Prevention Option:
PxWire Volume 14, Issue No. 2
The latest issue presents new research on the effectiveness of oral PrEP in cisgender women, new injectable cabotegravir approvals and rollout, and much more!
Prevention Option:
An Overview of Lenacapavir for PrEP Trials
The PURPOSE efficacy trials are expected to report results later this year or in early 2025. If the six-monthly injectable lenacapavir demonstrates safety and efficacy, it will be the next long-acting injectable PrEP option to enter the market—and it is not too early to plan.
Prevention Option:
Moving a Product to the Real World
To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.
Prevention Option:
Oral PrEP in Cisgender Women
Displayed in these two graphics: researchers documented patterns of adherence for oral PrEP and we graphed HIV incidence based on weekly F/TDF adherence in cisgender women.
Prevention Option:
Civil Society Voices at World Health Assembly
The annual World Health Assembly (WHA) is convening the last week of May in Geneva, Switzerland. As the decision-making body of the World Health Organization (WHO), amongst many other issues, the WHA will be attempting to finalize the Pandemic Accord after two years of ongoing negotiations.
PrEP Initiations by Country Worldwide
AVAC tracks global PrEP use by conducting quarterly surveys of ongoing oral PrEP demonstration and implementation projects, and collecting data from manufacturers and government agencies. This graphic shows data on PrEP initiations around the globe.
Prevention Option:
Expanding HIV Self-Testing Impact and Innovations from the STAR Initiative
This supplement presents major achievements and insights gained from the introduction, scale-up, and optimization of self-testing.
Prevention Option:
Join us as we Commemorate HIV Vaccine Awareness Day
As we prepare to commemorate HIV Vaccine Awareness Day (HVAD) on May 18, the field continues to see some modest scientific breakthroughs, while still facing extraordinary challenges.
showing 1-10 of 853